Welcome to Hologic Investor Relations

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems for breast and skeletal heath, GYN surgical products and medical aesthetic systems. With a broad range of market-leading technologies and a robust research and development program, Hologic is dedicated to The Science of Sure.

The Company's Common Stock is listed on the Nasdaq Global Select Market under the trading symbol HOLX.

Recent and Upcoming Events
Recent News
Mar 22, 2017

Hologic, Inc. (Nasdaq: HOLX) announced today that it has completed the acquisition of Cynosure, Inc., a leader in medical aesthetics systems and technologies, for $66 per share in cash. "We are...

Mar 1, 2017

MARLBOROUGH, Mass., March 1, 2017 — Hologic, Inc. (Nasdaq: HOLX) will highlight its portfolio of innovative, award-winning breast cancer screening and interventional products, including new...

Feb 15, 2017

Hologic, Inc. (Nasdaq: HOLX) announced today that the United States Food and Drug Administration (FDA) has granted PMA approval for the Company's hepatitis C virus (HCV) assay for quantitation of...

Feb 14, 2017

MARLBOROUGH, Mass., February 13, 2017 -- Hologic, Inc. (NASDAQ: HOLX) today announced the Company's Aptima® Zika Virus diagnostic assay is now CE marked in Europe for the detection and diagnosis...

More ›